|

luvometinib + anlotinib Clinical Trials

1 actively recruiting trial

Also known as: FCN-159+anlotinib

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1

Indications

  • Previous Treamted1
  • KRAS-mutated1
  • Non-small Cell Lung Caner1
  • Metastasis1
  • Lung Cancer1

Other1 trial

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.